495 Followers on Owler
Trovagene develops drug-based therapeutics that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers...
Read moreTrovagene develops drug-based therapeutics that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers...
Read more
News
Nov 03, 2022
Owler
Cardiff Oncology, Inc.: Cardiff Oncology's revenue changed from $384K in Jun 2022 to $391K in Sep 2022
May 13, 2020
BioSpace
Trovagene: Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
May 08, 2020
PR Newswire
Press Release: Trovagene : Trovagene Announces First Quarter 2020 Results and Highlights
May 07, 2020
Xconomy
Trovagene: Trovagene Rebrands as Cardiff Oncology, Promotes Longtime Exec to CEO
May 06, 2020
PR Newswire
Trovagene: Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer
Apr 22, 2020
PR Newswire
Press Release: Trovagene : Trovagene Expands Board with Addition of Three Industry Leaders - James Armitage, MD, Lle White, and Gary Pace, PhD
Apr 08, 2020
PR Newswire
Press Release: Trovagene : Trovagene to Present at the 19th Annual Needham Healthcare Conference
Apr 08, 2020
MARKETEXCLUSIVE
Trovagene: Trovagene, Inc. (NASDAQ:TROV) Files An 8-K Other Events
Mar 05, 2020
Market Exclusive
Trovagene: Trovagene, Inc. (NASDAQ:TROV) Files An 8-K Other Events
Feb 13, 2020
PR Newswire
Press Release: Trovagene : Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients
Cardiff Oncology Competitors
1
2
3
4
5
6
7
8
9
10
Looking for similar companies to Cardiff Oncology?
Cardiff Oncology Quarterly and Annual Revenue
Trailing 12-Months Trend (TTM)
Annual Revenue
$ < 1M
Cardiff Oncology's revenue is the ranked 14th among it's top 10 competitors. The top 10 competitors average 119.1M. Over the last four quarters, Cardiff Oncology's revenue has decreased by 30.1%. Specifically, in Q3 2022's revenue was $ < 1M; in Q2 2022, it was $ < 1M; in Q1 2022, it was $ < 1M; in Q4 2021, Cardiff Oncology's revenue was $ < 1M.
Cardiff Oncology News
Cardiff Oncology Press Releases
Cardiff Oncology Videos
Cardiff Oncology Headquarters
Cardiff Oncology Summary
ABOUT
Overview
Trovagene develops drug-based therapeutics that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers. Cardiff Oncology was founded in 1999. Cardiff Oncology's headquarters is located in San Diego, California, USA 921...Website
trovageneoncology.comCompetitors
View 13 Cardiff Oncology competitors here.Acquisitions
There have been no acquisitions found related to Cardiff OncologyInvestments
Recent investment data cannot be found related to Cardiff OncologyFrequently Asked Questions about Cardiff Oncology
When was Cardiff Oncology founded?
Cardiff Oncology was founded in 1999Who is Cardiff Oncology's CEO?
Cardiff Oncology's CEO is Mark ErlanderHow much revenue does Cardiff Oncology generate?
Cardiff Oncology generates $ < 1M in revenueHow much funding does Cardiff Oncology have?
Cardiff Oncology has historically raised $50M in funding
Where is Cardiff Oncology's headquarters?
Cardiff Oncology's headquarters is in San Diego California, USAHow many employees does Cardiff Oncology have?
Cardiff Oncology has 20 employeesWhat sector does Cardiff Oncology operate in?
Cardiff Oncology is in BiotechnologyWho are Cardiff Oncology's competitors?
Cardiff Oncology's top competitors are bluebird, Inovio, Genecast